Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR classical Hodgkin lymphoma patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieto, Yago, Gruschkus, Stephen, Valdez, Benigno C., Jones, Roy B., Anderlini, Paolo, Hosing, Chitra, Popat, Uday, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Saini, Neeraj, Srour, Samer, Rezvani, Katayoun, Ramdial, Jeremy, Barnett, Melissa, Gulbis, Alison, Shigle, Terri Lynn, Ahmed, Sairah, Iyer, Swaminathan, Lee, Hun, Nair, Ranjit, Parmar, Simrit, Steiner, Raphael, Dabaja, Bouthaina, Pinnix, Chelsea, Gunther, Jillian, Cuglievan, Branko, Mahadeo, Kris, Khazal, Sajad, Chuang, Hubert, Champlin, Richard, Shpall, Elizabeth J., Andersson, Borje S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968895/
https://www.ncbi.nlm.nih.gov/pubmed/33951890
http://dx.doi.org/10.3324/haematol.2021.278311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968895/
https://www.ncbi.nlm.nih.gov/pubmed/33951890
http://dx.doi.org/10.3324/haematol.2021.278311

Ejemplares similares